Allarity Therapeutics, Inc.

ALLRSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1860657

Concept	FY2024	FY2023	FY2022	FY2021
Gross Profit	—	-$2.3M	—	—
Research and Development Expense	$7.1M	$6.9M	$14.2M	$4.2M
Operating Expenses	$17.1M	$34.5M	$26.6M	$8.3M
Operating Income (Loss)	-$17.1M	-$34.5M	-$26.6M	-$8.3M
Interest Expense	—	$223.0K	$12.0K	$93.0K
Nonoperating Income (Expense)	$5.3M	$16.9M	$41.0K	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$11.8M	-$17.6M	—	—
Income Tax Expense (Benefit)	$83.0K	-$1.5M	$133.0K	$198.0K
Net Income (Loss) Attributable to Parent	-$11.9M	-$16.1M	-$26.6M	-$6.6M
Earnings Per Share, Basic	-$6.0K	-$3.1K	-$4.19	-$2.03
Earnings Per Share, Diluted	—	-$3.1K	-$4.19	—

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$11.9M	$14.5M	$49.6M	$33.4M
Assets, Current	$2.0M	$5.0M	$21.4M	$1.7M
Cash and Cash Equivalents, at Carrying Value	$166.0K	$2.0M	—	—
Liabilities	$14.6M	$12.7M	$30.8M	$9.0M
Liabilities, Current	$14.2M	$11.2M	$20.7M	$5.5M
Long-term Debt	$2.7M	—	$2.6M	—
Accounts Payable, Current	$8.4M	$6.3M	$698.0K	$2.1M
Stockholders' Equity Attributable to Parent	-$113.0K	$18.2M	$24.4M	$20.0M
Common Stock, Shares, Outstanding

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$12.7M	-$16.8M	-$14.9M	-$7.3M
Net Cash Provided by (Used in) Investing Activities	$0.00	$791.0K	$1.0M	-$3.0K
Net Cash Provided by (Used in) Financing Activities	$11.0M	-$1.3M	$33.8M	$6.0M
Payments to Acquire Property, Plant, and Equipment	$0.00	$18.0K	$18.0K	$3.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)